RVL Pharmaceuticals
JD Schaub currently serves as Executive Vice President and Chief Operating Officer at RVL Pharmaceuticals, Inc., a position held since December 2013. Prior to this role, JD Schaub was Executive Vice President of Commercial Operations and Chief Operating Officer at Osmotica/Vertical/Trigen, where tenure spanned from December 2013 to December 2021. JD Schaub’s earlier experience includes consulting for the healthcare industry at Avista Capital, serving as Vice President of M&A and Portfolio Strategy at Fougera Pharmaceuticals Inc., and holding various positions at Pfizer and King Pharmaceuticals, including Director of Business Development and Senior Manager of Business Development & Licensing. JD Schaub earned an MBA in Pharmaceutical Marketing and Management from Rutgers Business School and a Bachelor of Arts in Economics from Middlebury College.
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.